New biosimilar policy benefits industry, not patients: AMA

Strategies to drive up prescribing of biosimilar medicines in a bid to save PBS dollars are proving unpopular with clinicians, with the AMA opposing two new proposals. The government is consulting the medical world on a range of ‘uptake drivers’, which according to an AMA submission include plans to insert a ‘restriction’ note in the ...

Already a member?

Login to keep reading.

© 2021 the limbic